Bafameritin-M en es it fr

Bafameritin-M Brand names, Bafameritin-M Analogs

Bafameritin-M Brand Names Mixture

  • No information avaliable

Bafameritin-M Chemical_Formula


Bafameritin-M RX_link

Bafameritin-M fda sheet

Bafameritin-M msds (material safety sheet)

Bafameritin-M MSDS

Bafameritin-M Synthesis Reference

No information avaliable

Bafameritin-M Molecular Weight

241.285 g/mol

Bafameritin-M Melting Point

230-231 oC

Bafameritin-M H2O Solubility

20 mg/L

Bafameritin-M State


Bafameritin-M LogP


Bafameritin-M Dosage Forms

Bolus; Capsule; Capsule (enteric-coated); Drops; Liquid; Lotion; Powder; Powder for solution; Shampoo; Soap bar; Solution; Stick; Syrup; Tablet; Tablet (extended-release)

Bafameritin-M Indication

For the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever.

Bafameritin-M Pharmacology

Mefenamic acid, an anthranilic acid derivative, is a member of the fenamate group of nonsteroidal anti-inflammatory drugs (NSAIDs). It exhibits anti-inflammatory, analgesic, and antipyretic activities. Similar to other NSAIDs, mefenamic acid inhibits prostaglandin synthetase.

Bafameritin-M Absorption

Mefenamic acid is rapidly absorbed after oral administration.

Bafameritin-M side effects and Toxicity

Oral, rat LD50: 740 mg/kg. Symptoms of overdose may include severe stomach pain, coffee ground-like vomit, dark stool, ringing in the ears, change in amount of urine, unusually fast or slow heartbeat, muscle weakness, slow or shallow breathing, confusion, severe headache or loss of consciousness.

Bafameritin-M Patient Information

Bafameritin-M Organisms Affected

Humans and other mammals